GL1X · GenesisL1 explorer

MolNFT v1 · #23796 · protein

Crystal structure of antibody 19G2 with hapten at 100K

1UB5 · Antibody 19G2, alpha chain: “Crystal structure of antibody 19G2 with hapten at 100K”. X-ray diffraction, 1 ligand (SPB), 11 pockets (best druggability 0.76). MolNFT v1 #23796 on GenesisL1: 3D structure, binding sites and pockets in…

PDB
1UB5
Type
protein
Length
846 residues
Chains
4
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Antibody 19G2, alpha chain; Antibody 19G2, beta chain
UniProt
P18527
Ligands
SPB
Pockets
11 · best druggability 0.76

Structure

x-ray diffraction · 2 distinct chains · 6% helix, 49% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
H, AAntibody 19G2, alpha chainprotein2096% helix, 50% strandP18527
L, BAntibody 19G2, beta chainprotein2146% helix, 48% strand—

Ligands and binding sites

  • SPB · 4-(4-styryl-phenylcarbamoyl)-butyric acid · ligand · 2 copies · chains H, L, A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

11 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11380.760.9324SPB
21550.750.9226SPB
36310.640.7555empty
42800.520.7437empty
51130.480.7923empty

Interfaces

2 interfaces between chains.

  • H–L · 1767 Ų buried · 16 hydrogen bonds · protein-protein
  • A–B · 1722 Ų buried · 16 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 8 disulfide (disulfide).

Compared structures

  • 1UB5 · Crystal structure of Antibody 19G2 with hapten at 100K · the same entry in another collection · chain H against H, TM-score 1.00
  • P18527 · AlphaFold monomer V2.0 prediction for ig heavy chain V region 914 (P18527) · a predicted model of the same protein · chain H against A, TM-score 0.45

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.